Monday, October 15, 2018

2 Studies Look at the Role of Aspirin and NSAIDs in Ovarian Cancer

JAMA Oncology (Oct 2018) and Lancet Oncology (Aug 2018) published research results that dove-tailed each other.

In the Lancet study entitled "Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NIH/NIHII): a cohort study", the objective was to determine if regular use of aspirin, non-steroidal anti-inflammatory medications (NSAIDs) or paracetamol before and after diagnosis of epithelial ovarian cancer improved survival.

To do this, they looked at health outcomes from two, very large on-going studies: the Nurses Health Study (NHS) begun in 1976 and the Nurses Health Study II (NHSII), begun in 1989. These two studies rely on completed biennial self-reported questionnaires. Those women who had confirmed StageI-III epithelial OC were included in the study.

The results: "Recent  use of aspirin or non-aspirin NSAIDs, defined as current use in the past 2 years, after diagnosis appears to improve ovarian cancer-specific survival." They go on to say that further research needs to be done to determine timing and dosing and use w/traditional chemotherapies.

The second study was entitled, "Association of Analgesic Use with Risk of Ovarian Cancer in the Nurses' Health Studies." This study examined the use of analgesics in reducing the risk of developing ovarian cancer. Smaller case controlled studies showed correlation and they wanted to see if these results held using much larger samples. What they found was I think, quite interesting.

The use of low dose aspirin reduced the risk of developing ovarian cancer by 23% compared to non-users. However, "current use of nonaspirin NSAIDs was associated with a 19% higher risk of ovarian cancer compared with nonuse."


No comments:

Post a Comment